-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Faron Pharmaceuticals Oy (LON:FARN) Share Price Passes Above 50 Day Moving Average of $176.78
Faron Pharmaceuticals Oy (LON:FARN) Share Price Passes Above 50 Day Moving Average of $176.78
Faron Pharmaceuticals Oy (LON:FARN – Get Rating) shares passed above its 50 day moving average during trading on Tuesday . The stock has a 50 day moving average of GBX 176.78 ($2.08) and traded as high as GBX 239 ($2.81). Faron Pharmaceuticals Oy shares last traded at GBX 232.50 ($2.73), with a volume of 30,156 shares traded.
Faron Pharmaceuticals Oy Stock Performance
The company has a market capitalization of £143.53 million and a P/E ratio of -6.48. The business has a 50-day moving average of GBX 176.78 and a 200-day moving average of GBX 197.63. The company has a debt-to-equity ratio of 121.51, a current ratio of 1.70 and a quick ratio of 1.09.
Faron Pharmaceuticals Oy Company Profile
(Get Rating)
Faron Pharmaceuticals Oy operates as a clinical stage drug discovery and development company. The company develops a pipeline of immune modulation based proprietary drug candidates for unmet need, including immuno-oncology, and organ protection and regenerative medicine. Its lead product candidates are Traumakine, an intravenous interferon beta-1a therapy for the treatment of acute respiratory distress syndrome, COVID-19, acute kidney injury, cardiac protection, solid organ transplant, and ischemia reperfusion injury; and Bexmarilimab, a novel precision cancer immunotherapy candidate for treating solid tumors, non-small cell lung carcinoma, and hematological malignancies.
Further Reading
- Power Integrations Stock Can Power Your Portfolio
- Don't Chase Walmart Higher, Wait For Extra Low Prices
- Home Depot Results (and Institutions) Are A Catalyst For Lowe's?
- Agilent Remains In Buy Range Ahead Of Next Week's Q4 Report
- Three Penny Stocks Making Big Moves In November
Receive News & Ratings for Faron Pharmaceuticals Oy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Faron Pharmaceuticals Oy and related companies with MarketBeat.com's FREE daily email newsletter.
Faron Pharmaceuticals Oy (LON:FARN – Get Rating) shares passed above its 50 day moving average during trading on Tuesday . The stock has a 50 day moving average of GBX 176.78 ($2.08) and traded as high as GBX 239 ($2.81). Faron Pharmaceuticals Oy shares last traded at GBX 232.50 ($2.73), with a volume of 30,156 shares traded.
在周二的交易中,Faron PharmPharmticals Oy(LON:FARN-GET Rating)的股价超过了50日移动平均线。该股的50日移动均线为176.78英镑(合2.08美元),交易价格高达239英镑(合2.81美元)。Faron PharmPharmticals Oy的股票最后交易价格为232.50英镑(合2.73美元),成交量为30,156股。
Faron Pharmaceuticals Oy Stock Performance
Faron制药公司的股票表现
The company has a market capitalization of £143.53 million and a P/E ratio of -6.48. The business has a 50-day moving average of GBX 176.78 and a 200-day moving average of GBX 197.63. The company has a debt-to-equity ratio of 121.51, a current ratio of 1.70 and a quick ratio of 1.09.
该公司市值为1.4353亿GB,市盈率为-6.48。该业务的50日移动均线切入位在176.78英镑,200日移动均线切入位在197.63英镑。该公司的债务权益比率为121.51,流动比率为1.7,速动比率为1.09。
Faron Pharmaceuticals Oy Company Profile
Faron制药公司简介
(Get Rating)
(获取评级)
Faron Pharmaceuticals Oy operates as a clinical stage drug discovery and development company. The company develops a pipeline of immune modulation based proprietary drug candidates for unmet need, including immuno-oncology, and organ protection and regenerative medicine. Its lead product candidates are Traumakine, an intravenous interferon beta-1a therapy for the treatment of acute respiratory distress syndrome, COVID-19, acute kidney injury, cardiac protection, solid organ transplant, and ischemia reperfusion injury; and Bexmarilimab, a novel precision cancer immunotherapy candidate for treating solid tumors, non-small cell lung carcinoma, and hematological malignancies.
Faron PharmPharmticals Oy是一家临床阶段药物发现和开发公司。该公司开发了一系列基于免疫调节的专利候选药物,以满足未得到满足的需求,包括免疫肿瘤学、器官保护和再生医学。它的主要候选产品是Traumakine,一种静脉注射干扰素β-1a疗法,用于治疗急性呼吸窘迫综合征、新冠肺炎、急性肾损伤、心脏保护、实体器官移植和缺血再灌注损伤;以及Bexmarilimab,一种新的精密癌症免疫疗法候选药物,用于治疗实体瘤、非小细胞肺癌和血液系统恶性肿瘤。
Further Reading
进一步阅读
- Power Integrations Stock Can Power Your Portfolio
- Don't Chase Walmart Higher, Wait For Extra Low Prices
- Home Depot Results (and Institutions) Are A Catalyst For Lowe's?
- Agilent Remains In Buy Range Ahead Of Next Week's Q4 Report
- Three Penny Stocks Making Big Moves In November
- 电源整合股票可以为您的投资组合提供动力
- 不要追逐沃尔玛更高,等待超低价格
- 家得宝的业绩(和机构)是劳氏的催化剂吗?
- 安捷伦在下周第四季度报告发布前仍在买入区间
- 三只细价股在11月大动干戈
Receive News & Ratings for Faron Pharmaceuticals Oy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Faron Pharmaceuticals Oy and related companies with MarketBeat.com's FREE daily email newsletter.
接受Faron制药Oy Daily的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Faron PharmPharmticals Oy和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧